Skip to main content

Table 4 Positive and negative RECIST 1.1 responses after intraarterial chemotherapy and targeted therapy, using protocols selected by positive or negative CTC chemosensitivity and tumor gene expression analyses

From: Circulating tumour cell gene expression and chemosensitivity analyses: predictive accuracy for response to multidisciplinary treatment of patients with unresectable refractory recurrent rectal cancer or unresectable refractory colorectal cancer liver metastases

 

RECIST 1.1 Response to intra-arterial chemotherapy and targeted therapy selected by CTC chemosensitivity and tumor gene expression analyses

 

CTC chemosensitivity assays for intra-arterial chemotherapy and CTC tumor gene expression assays for targeted therapy

Positive patient responses (CR + PR)

Negative patient responses (SD + PD)

Total

Positive test [CTC death ≥70% plus Gene overexpression ≥50%]

16

18

34

Negative test [CTC death < 70% plus Gene overexpression < 50%]

1

1

2

Total

17

19

36

  1. CTC Circulating tumor cell, CR Complete response, PR Partial response, SD Stable disease, PD Progressive disease